Poliomyelitis - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 4, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Poliomyelitis - Overview
Poliomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Poliomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Poliomyelitis - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech International Ltd
Biological E Ltd
Biological Mimetics Inc
Boryung Pharmaceutical Co Ltd
Daiichi Sankyo Company Ltd
GlaxoSmithKline Plc
Grifols SA
Johnson & Johnson
Kaketsuken KK
LG Chem, Ltd.
Nanolek
Panacea Biotec Ltd
Sanofi
Sanofi Pasteur SA
Sentinext Therapeutics Sdn Bhd
Shantha Biotechnics Pvt Ltd
Taiga Biotechnologies Inc
Takeda Pharmaceutical Company Ltd
Poliomyelitis - Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTaP-IPV-HB-PRPT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ImmunoRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPVGVI-3000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-2348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polio (virus like particle, bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polio [strain Sabin] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poliomyelitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poliomyelitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poliomyelitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poliomyelitis - Dormant Projects
Poliomyelitis - Discontinued Products
Poliomyelitis - Product Development Milestones
Featured News & Press Releases
Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
May 11, 2011: Sanofi Pasteur Launches Pentaxim In China
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Poliomyelitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H1 2017
Poliomyelitis - Pipeline by Biological E Ltd, H1 2017
Poliomyelitis - Pipeline by Biological Mimetics Inc, H1 2017
Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H1 2017
Poliomyelitis - Pipeline by Grifols SA, H1 2017
Poliomyelitis - Pipeline by Johnson & Johnson, H1 2017
Poliomyelitis - Pipeline by Kaketsuken KK, H1 2017
Poliomyelitis - Pipeline by LG Chem, Ltd., H1 2017
Poliomyelitis - Pipeline by Nanolek, H1 2017
Poliomyelitis - Pipeline by Panacea Biotec Ltd, H1 2017
Poliomyelitis - Pipeline by Sanofi, H1 2017
Poliomyelitis - Pipeline by Sanofi Pasteur SA, H1 2017
Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2017
Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2017
Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H1 2017
Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Poliomyelitis - Dormant Projects, H1 2017
Poliomyelitis - Discontinued Products, H1 2017